Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VACCINEX, INC.VCNX · Entity 9673 | 10% owner | August 13, 2018 | August 15, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VACCINEX, INC.
Report date August 13, 2018 · Filed August 15, 2018
Jointly reported with Antibody Investments LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,346,139 |
Reported balance
After 2018-08-13 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-08-13 · Conversion · Acquired 1,346,139 · Balance 1,346,139 F1: The reported securities converted into shares of Common Stock on a 0.1868-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. |
| Common StockSEC Table I · non-derivative | Direct | 1,895,583 |
Reported balance
After 2018-08-13 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-08-13 · Conversion · Acquired 549,444 · Balance 1,895,583 F2: The reported securities converted into shares of Common Stock on a 1-for-10 basis immediately prior to the consummation of the Issuer's initial public offering. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-08-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-08-13 · Conversion · Disposed 7,205,882 · Balance 0 F1: The reported securities converted into shares of Common Stock on a 0.1868-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. |
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-08-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-08-13 · Conversion · Disposed 5,494,505 · Balance 0 F2: The reported securities converted into shares of Common Stock on a 1-for-10 basis immediately prior to the consummation of the Issuer's initial public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities converted into shares of Common Stock on a 0.1868-for-1 basis immediately prior to the consummation of the Issuer's initial public offering.
F2: The reported securities converted into shares of Common Stock on a 1-for-10 basis immediately prior to the consummation of the Issuer's initial public offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2018 Filed Aug 15, 2018 16:49 UTC | VACCINEX, INC. VCNX · Entity 9673 | ConversionSeries D Convertible Preferred Stock · Derivative | 5,494,505 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-18-000927 · edgar.xml · derivative · entry 4 Antibody Investments LLC · CIK 0001749340 · 10% owner Shumacher Michael · CIK 0001749366 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 549,444 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The reported securities converted into shares of Common Stock on a 1-for-10 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · price: The reported securities converted into shares of Common Stock on a 1-for-10 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · derivative.exercise_date: The reported securities converted into shares of Common Stock on a 1-for-10 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · derivative.expiration_date: The reported securities converted into shares of Common Stock on a 1-for-10 basis immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 16:49 UTC | VACCINEX, INC. VCNX · Entity 9673 | ConversionSeries C Convertible Preferred Stock · Derivative | 7,205,882 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-18-000927 · edgar.xml · derivative · entry 3 Antibody Investments LLC · CIK 0001749340 · 10% owner Shumacher Michael · CIK 0001749366 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,346,139 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The reported securities converted into shares of Common Stock on a 0.1868-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The reported securities converted into shares of Common Stock on a 0.1868-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The reported securities converted into shares of Common Stock on a 0.1868-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.expiration_date: The reported securities converted into shares of Common Stock on a 0.1868-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 16:49 UTC | VACCINEX, INC. VCNX · Entity 9673 | ConversionCommon Stock | 549,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-18-000927 · edgar.xml · nonDerivative · entry 2 Antibody Investments LLC · CIK 0001749340 · 10% owner Shumacher Michael · CIK 0001749366 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,895,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The reported securities converted into shares of Common Stock on a 1-for-10 basis immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 16:49 UTC | VACCINEX, INC. VCNX · Entity 9673 | ConversionCommon Stock | 1,346,139 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-18-000927 · edgar.xml · nonDerivative · entry 1 Antibody Investments LLC · CIK 0001749340 · 10% owner Shumacher Michael · CIK 0001749366 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,346,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The reported securities converted into shares of Common Stock on a 0.1868-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.